{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:38:50Z","timestamp":1794281930008,"version":"4.9.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.autrev.2026.104088","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:37:26Z","timestamp":1779899846000},"page":"104088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and clinical correlates of infection in idiopathic inflammatory myopathies: A systematic review and meta-analysis of 14,548 patients"],"prefix":"10.1016","volume":"25","author":[{"given":"Gaodi","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anji","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.autrev.2026.104088_bb0005","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/S2665-9913(23)00322-3","article-title":"Idiopathic inflammatory myopathies: current insights and future frontiers","volume":"6","author":"Connolly","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104088_bb0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104088_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104088_bb0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11926-020-0883-0","article-title":"Pneumocystis Jirovecii pneumonia and other infections in idiopathic inflammatory myositis","volume":"22","author":"Mecoli","year":"2020","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.autrev.2026.104088_bb0025","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3892\/etm.2016.3006","article-title":"Investigation into the cause of mortality in 49 cases of idiopathic inflammatory myopathy: a single center study","volume":"11","author":"Xiao","year":"2016","journal-title":"Exp Ther Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104088_bb0030","doi-asserted-by":"crossref","first-page":"254","DOI":"10.55563\/clinexprheumatol\/yps7ai","article-title":"Infection is not rare in patients with idiopathic inflammatory myopathies","volume":"40","author":"Ge","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104088_bb0035","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s10067-024-06899-3","article-title":"Prognostic factors of fungal infection in anti-melanoma differentiation-associated gene 5 antibody-positive associated interstitial lung disease","volume":"43","author":"Zhou","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104088_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2025.110431","article-title":"A nomogram for the prediction of co-infection in MDA5 dermatomyositis: a rapid clinical assessment model","volume":"272","author":"Wu","year":"2025","journal-title":"Clin Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104088_bb0045","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1093\/rheumatology\/kead063","article-title":"High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody-positive dermatomyositis","volume":"62","author":"Chen","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104088_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1504380","article-title":"Pneumocystis jirovecii pneumonia increases the 3-months mortality of anti-MDA5-antibody-positive dermatomyositis patients","volume":"15","author":"Gao","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104088_bb0055","first-page":"218","article-title":"Pneumocystis jirovecii pneumonia in anti-MDA5-positive dermatomyositis: characterisation, risk factors and prognosis","volume":"44","author":"Yang","year":"2026","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104088_bb0060","first-page":"210","article-title":"Analysis of clinical features and risk factors for patients with idiopathic inflammatory myopathy complicated by Pneumocystis jirovecii pneumonia","volume":"44","author":"Li","year":"2026","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104088_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103713","article-title":"Characteristics and risk factors for infection in patients with ANCA-associated vasculitis: a systematic review and meta-analysis","volume":"24","author":"Luo","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2026.104088_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102997","article-title":"Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: a systematic review and meta-analysis","volume":"21","author":"Goswami","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2026.104088_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103335","article-title":"The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis\/polymyositis adults: a systematic review and meta-analysis","volume":"22","author":"Wang","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"15","key":"10.1016\/j.autrev.2026.104088_bb0080","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.autrev.2026.104088_bb0085","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.autrev.2026.104088_bb0090","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104088_bb0095","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"10.1016\/j.autrev.2026.104088_bb0100","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2026.104088_bb0105","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104088_bb0110","doi-asserted-by":"crossref","first-page":"377","DOI":"10.6028\/jres.087.022","article-title":"Consensus values and weighting factors","volume":"87","author":"Paule","year":"1982","journal-title":"J Res Natl Bur Stand (1977)"},{"issue":"9","key":"10.1016\/j.autrev.2026.104088_bb0115","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1177\/0962280219889080","article-title":"Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis","volume":"29","author":"McGrath","year":"2020","journal-title":"Stat Methods Med Res"},{"issue":"12","key":"10.1016\/j.autrev.2026.104088_bb0120","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1177\/09622802211047348","article-title":"Estimating the sample mean and standard deviation from order statistics and sample size in meta-analysis","volume":"30","author":"Cai","year":"2021","journal-title":"Stat Methods Med Res"},{"issue":"2","key":"10.1016\/j.autrev.2026.104088_bb0125","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10067-022-06403-9","article-title":"Clinical characteristics of and risk factors for Pneumocystis jirovecii pneumonia in anti-melanoma differentiation-associated gene 5 (Anti-MDA5) antibody-positive dermatomyositis patients: a single-center retrospective study","volume":"42","author":"Li","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2026.104088_bb0130","doi-asserted-by":"crossref","first-page":"16303","DOI":"10.1038\/srep16303","article-title":"The increased risk of active tuberculosis disease in patients with dermatomyositis - a nationwide retrospective cohort study","volume":"5","author":"Wu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2026.104088_bb0135","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.2147\/JIR.S460702","article-title":"Prevalence, risk factors, and mortality of invasive pulmonary aspergillosis in patients with Anti-MDA5+ dermatomyositis: a retrospective STUDY in China","volume":"17","author":"Chen","year":"2024","journal-title":"J Inflamm Res"},{"issue":"12","key":"10.1016\/j.autrev.2026.104088_bb0140","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1093\/rheumatology\/keq279","article-title":"Infections in polymyositis and dermatomyositis: analysis of 192 cases","volume":"49","author":"Chen","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.autrev.2026.104088_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10123176","article-title":"Infection risk in patients with dermatomyositis associated with Anti-MDA5 antibodies: a historical cohort study","volume":"10","author":"Billet","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2026.104088_bb0150","article-title":"Development and validation of a nomogram for predicting the incidence of infectious events in patients with idiopathic inflammatory myopathies","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104088_bb0155","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/1346-8138.15409","article-title":"Demographic and clinical characteristics of cytomegalovirus reactivation in dermatomyositis","volume":"47","author":"Sekiguchi","year":"2020","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104088_bb0160","doi-asserted-by":"crossref","first-page":"621","DOI":"10.6061\/clinics\/2013(05)07","article-title":"Chloroquine diphosphate: a risk factor for herpes zoster in patients with dermatomyositis\/polymyositis","volume":"68","author":"Cunha","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.autrev.2026.104088_bb0165","first-page":"280","article-title":"Novel innate immunity predictors of infections in idiopathic inflammatory myopathies patients: a cohort study","volume":"74","author":"G\u00f3mez-Mart\u00edn","year":"2022","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104088_bb0170","first-page":"3683","article-title":"Hepatitis B exposure and infection in idiopathic inflammatory myopathies: prevalence, presentation, and treatment response","volume":"74","author":"Valle","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104088_bb0175","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-019-1997-5","article-title":"Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study","volume":"21","author":"Hsu","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.autrev.2026.104088_bb0180","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1093\/rheumatology\/kead034","article-title":"Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with anti-Melanoma Differentiation-Associated Gene 5","volume":"62","author":"Liu","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.autrev.2026.104088_bb0185","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.11150\/kansenshogakuzasshi1970.64.1394","article-title":"Herpes zoster in patients with polymyositis and dermatomyositis","volume":"64","author":"Nagaoka","year":"1990","journal-title":"Kansenshogaku Zasshi"},{"issue":"8","key":"10.1016\/j.autrev.2026.104088_bb0190","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archdermatol.2009.152","article-title":"Incidence, risk factors, and severity of herpesvirus infections in a cohort of 121 patients with primary dermatomyositis and dermatomyositis associated with a malignant neoplasm","volume":"145","author":"Fardet","year":"2009","journal-title":"Arch Dermatol"},{"issue":"28","key":"10.1016\/j.autrev.2026.104088_bb0195","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001138","article-title":"Increased risk of Herpes zoster following dermatomyositis and polymyositis: a nationwide population-based cohort study","volume":"94","author":"Tsai","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.autrev.2026.104088_bb0200","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/1756-185X.13255","article-title":"Opportunistic infections in patients with idiopathic inflammatory myopathies","volume":"21","author":"Redondo-Benito","year":"2018","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104088_bb0205","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12088-024-01333-3","article-title":"The characteristics and risk factors of cytomegalovirus infection in dermatomyositis","volume":"65","author":"Zhang","year":"2025","journal-title":"Indian J Microbiol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104088_bb0210","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1506-7","article-title":"The predictive prognostic factors for polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"20","author":"Sugiyama","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104088_bb0215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semarthrit.2010.08.003","article-title":"Infectious complications in polymyositis and dermatomyositis: a series of 279 patients","volume":"41","author":"Marie","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2026.104088_bb0220","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/1346-8138.15274","article-title":"Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis","volume":"47","author":"Matsuda","year":"2020","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104088_bb0225","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13075-021-02606-8","article-title":"High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center","volume":"23","author":"Huang","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.autrev.2026.104088_bb0230","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1093\/rheumatology\/keab015","article-title":"High burden of infections in Indian patients with Idiopathic Inflammatory Myopathy: validation of observations from the MyoCite dataset","volume":"60","author":"Chatterjee","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2026.104088_bb0235","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ard.2025.05.665","article-title":"POS0278 risk factors and prognostic outcomes of patients with idiopathic inflammatory myopathy complicated with infection","author":"Zhao","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104088_bb0240","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/rheumatology\/keaa436","article-title":"Risk factors associated with Pneumocystis jirovecii pneumonia in juvenile myositis in North America","volume":"60","author":"Sabbagh","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2026.104088_bb0245","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.autrev.2026.104088_bb0250","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","article-title":"Morbidity and mortality in adult polymyositis and dermatomyositis","volume":"14","author":"Marie","year":"2012","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"10.1016\/j.autrev.2026.104088_bb0255","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00296-017-3799-x","article-title":"Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain","volume":"37","author":"Nu\u00f1o-Nu\u00f1o","year":"2017","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.autrev.2026.104088_bb0260","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10067-006-0441-9","article-title":"Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review","volume":"26","author":"Falagas","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104088_bb0265","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O\u2019Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104088_bb0270","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress","volume":"20","author":"Lu","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104088_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2026.152967","article-title":"Immune dysregulation and infection susceptibility in Anti-MDA5 dermatomyositis","volume":"78","author":"Moore","year":"2026","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2026.104088_bb0280","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3899\/jrheum.170165","article-title":"HLA-DRB1 alleles as genetic risk factors for the development of Anti-MDA5 antibodies in patients with dermatomyositis","volume":"44","author":"Chen","year":"2017","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104088_bb0285","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/tan.13171","article-title":"Genetic association of HLA-DRB1 multiple polymorphisms with dermatomyositis in Chinese population","volume":"90","author":"Lin","year":"2017","journal-title":"Hla"},{"issue":"11","key":"10.1016\/j.autrev.2026.104088_bb0290","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/art.34657","article-title":"Brief report: association of HLA-DRB1*0101\/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population","volume":"64","author":"Gono","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104088_bb0295","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1807571","article-title":"Autoimmune idiopathic inflammatory myopathies: pharmacological differences and similarities by type of myositis and by sociodemographic variables","volume":"2022","author":"Valladales-Restrepo","year":"2022","journal-title":"Int J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104088_bb0300","doi-asserted-by":"crossref","first-page":"17172","DOI":"10.1038\/s41598-023-44092-9","article-title":"Characteristics and risk of interstitial lung disease in dermatomyositis and polymyositis: a retrospective cohort study in Japan","volume":"13","author":"Hu","year":"2023","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.autrev.2026.104088_bb0305","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.chest.2023.01.031","article-title":"Diagnosis and management of myositis-associated lung disease","volume":"163","author":"Hallowell","year":"2023","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.autrev.2026.104088_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154441","article-title":"Dermatomyositis and polymyositis in the intensive care unit: a single-center retrospective cohort study of 102 patients","volume":"11","author":"Peng","year":"2016","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.autrev.2026.104088_bb0315","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00296-023-05336-z","article-title":"Management of myositis associated interstitial lung disease","volume":"43","author":"Thong","year":"2023","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2026.104088_bb0320","article-title":"Microbiome features in bronchoalveolar lavage fluid of patients with idiopathic inflammatory myopathy-related interstitial lung disease","volume":"11","author":"Zhang","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2026.104088_bb0325","article-title":"Role of the microbiome in interstitial lung diseases","volume":"8","author":"Chioma","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"10.1016\/j.autrev.2026.104088_bb0330","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/1346-8138.15526","article-title":"Clinical features of anti-transcription intermediary factor 1\u03b3 (TIF1\u03b3)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1\u03b3 expression in tumors in the pathogenesis of cancer-associated dermatomyositis","volume":"47","author":"Motegi","year":"2020","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104088_bb0335","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s10067-025-07392-1","article-title":"Characteristics and prognostic analysis of Pneumocystis jirovecii pneumonia in connective tissue diseases patients with interstitial lung disease: a retrospective study","volume":"44","author":"Shi","year":"2025","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104088_bb0340","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/key357","article-title":"The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis","volume":"58","author":"Oldroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.autrev.2026.104088_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103464","article-title":"Clinical features of dermatomyositis patients with anti-TIF1 antibodies: a case based comprehensive review","volume":"22","author":"Kilinc","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2026.104088_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072150","article-title":"The impact of dysphagia in myositis: a systematic review and meta-analysis","volume":"9","author":"Labeit","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104088_bb0355","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-024-05073-0","article-title":"Septic shock in the immunocompromised cancer patient: a narrative review","volume":"28","author":"Nates","year":"2024","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.autrev.2026.104088_bb0360","first-page":"373","article-title":"A systematic review and metaanalysis of predictors of mortality in idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"50","author":"Hannah","year":"2023","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104088_bb0365","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104088_bb0370","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.70143","article-title":"Targeted therapy for idiopathic inflammatory myopathy","volume":"16","author":"Wang","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5","key":"10.1016\/j.autrev.2026.104088_bb0375","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2026.104088_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103264","article-title":"The role of bDMARDs in idiopathic inflammatory myopathies: a systematic literature review","volume":"22","author":"Grazzini","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2026.104088_bb0385","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-023-03100-z","article-title":"Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody","volume":"25","author":"Wang","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.autrev.2026.104088_bb0390","first-page":"671","article-title":"Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience","volume":"35","author":"Mecoli","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104088_bb0395","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/cid\/ciy723","article-title":"Prevalence and etiology of community-acquired pneumonia in immunocompromised patients","volume":"68","author":"Di Pasquale","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104088_bb0400","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00134-019-05906-5","article-title":"Diagnosis of severe respiratory infections in immunocompromised patients","volume":"46","author":"Azoulay","year":"2020","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.autrev.2026.104088_bb0405","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.autrev.2026.104088_bb0410","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/annonc\/mdu192","article-title":"Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)","volume":"26","author":"Maschmeyer","year":"2015","journal-title":"Ann Oncol"},{"issue":"Rr-16","key":"10.1016\/j.autrev.2026.104088_bb0415","first-page":"1","volume":"51","author":"Boyce","year":"2002","journal-title":"MMWR Recomm Rep"},{"issue":"30","key":"10.1016\/j.autrev.2026.104088_bb0420","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:29:01Z","timestamp":1790494141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":84,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1568997226001023"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104088","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and clinical correlates of infection in idiopathic inflammatory myopathies: A systematic review and meta-analysis of 14,548 patients","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104088"}}